低危脑膜瘤:NRG Oncology/RTOG 0539 的初步结果
这项 II 期试验将新诊断的 WHO 1 级脑膜瘤患者按全切除或次全切除后观察归为低危组,60 例可评估患者中位随访 9.1 年,3 年无进展生存率达 91.4%,但次全切除后 10 年无进展生存率仅 72.7%,提示该亚组可能需要辅助治疗。
要点
- 低危脑膜瘤术后观察的 3 年无进展生存率为 91.4%(95%CI 84.2-98.6)。
- 中心确认全切除者 3/5/10 年无进展生存率均为 94.3%/94.3%/87.6%。
- 次全切除者 10 年无进展生存率为 72.7%,作者提出该亚组可能受益于辅助治疗。
核心结论
- 这些结果前瞻性验证了低危脑膜瘤手术治疗后的高无进展生存率和总生存率,但对次全切除后的最佳管理提出疑问,该亚组可能潜在受益于辅助治疗。
研究设计与样本
- II 期试验 NRG/RTOG 0539 按世界卫生组织分级、复发状态和切除程度将患者分配至三组之一。
- 低危患者为新诊断的 1 级脑膜瘤,接受全切除或次全切除,术后观察。
- 主要终点为 3 年无进展生存率,不良事件采用不良事件通用术语标准(CTCAE)第 3 版评分。
- 共 60 例可评估患者,中位随访 9.1 年。
主要发现
- 60 例可评估患者中,3 年、5 年和 10 年无进展生存率分别为 91.4%(95%CI 84.2-98.6)、89.4%(95%CI 81.3-97.5)和 85.0%(95%CI 75.3-94.7)。
- 3 年、5 年和 10 年总生存率分别为 98.3%(95%CI 94.9-100)、98.3%(95%CI 94.9-100)和 93.8%(95%CI 87.0-100)。
- 中心确认全切除者 3/5/10 年无进展生存率分别为 94.3%/94.3%/87.6%,总生存率分别为 97.1%/97.1%/90.4%。
- 次全切除者 3/5/10 年无进展生存率分别为 83.1%/72.7%/72.7%,10 年总生存率为 100%。
- 5 例患者报告 1 例 3 级、4 例 2 级和 5 例 1 级不良事件,无 4 级或 5 级不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three- and five-year progression-free survival (PFS) for low-risk meningioma managed with surgery and observation reportedly exceeds 90%. Herewith we summarize outcomes for low-risk meningioma patients enrolled on NRG/RTOG 0539. METHODS: This phase II trial allocated patients to one of three groups per World Health Organization grade, recurrence status, and resection extent. Low-risk patients had either gross total (GTR) or subtotal resection (STR) for a newly diagnosed grade 1 meningioma and were observed after surgery. The primary endpoint was 3-year PFS. Adverse events (AEs) were scored using Common Terminology Criteria for Adverse Events (CTCAE) version 3. RESULTS: Among 60 evaluable patients, the median follow-up was 9.1 years. The 3-, 5-, and 10-year rates were 91.4% (95% CI, 84.2 to 98.6), 89.4% (95% CI, 81.3 to 97.5), 85.0% (95% CI, 75.3 to 94.7) for PFS and 98.3% (95% CI, 94.9 to 100), 98.3%, (95% CI, 94.9 to 100), 93.8% (95% CI, 87.0 to 100) for overall survival (OS), respectively. With centrally confirmed GTR, 3/5/10y PFS and OS rates were 94.3/94.3/87.6% and 97.1/97.1/90.4%. With STR, 3/5/10y PFS rates were 83.1/72.7/72.7% and 10y OS 100%. Five patients reported one grade 3, four grade 2, and five grade 1 AEs. There were no grade 4 or 5 AEs. CONCLUSIONS: These results prospectively validate high PFS and OS for low-risk meningioma managed surgically but raise questions regarding optimal management following STR, a subcohort that could potentially benefit from adjuvant therapy.
引用
- Rogers CL, Pugh SL, Vogelbaum MA, et al. Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. Neuro Oncol. 2023. PMID: 35657335. doi:10.1093/neuonc/noac137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。